Search results
Results from the WOW.Com Content Network
CA-125 was initially detected using the murine monoclonal antibody designated OC125. Robert Bast , Robert Knapp and their research team first isolated this monoclonal antibody in 1981. [ 28 ] The protein was named "cancer antigen 125" because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied.
Reference ranges (reference intervals) for blood tests are sets of values used by a health professional to interpret a set of medical test results from blood samples. Reference ranges for blood tests are studied within the field of clinical chemistry (also known as "clinical biochemistry", "chemical pathology" or "pure blood chemistry"), the ...
The tumor marker CA-125 is frequently elevated in endometrial cancer and can be used to monitor response to treatment, particularly in serous cell cancer or advanced disease. [ 32 ] [ 44 ] [ 82 ] Periodic MRIs or CT scans may be recommended in advanced disease and women with a history of endometrial cancer should receive more frequent pelvic ...
The one biomarker that has been in use over the last 20 years is CA-125. [121] A 2016 review found that this biomarker was present in those with symptoms of endometriosis; and, once ovarian cancer has been ruled out, a positive CA-125 may confirm the diagnosis. [122] Its performance in ruling out endometriosis is low. [122]
CA-125 levels are not accurate in early stage ovarian cancer, as half of stage I ovarian cancer patients have a normal CA-125 level. [ 31 ] [ 29 ] CA-125 may also be elevated in benign (non-cancerous) conditions, including endometriosis , pregnancy , uterine fibroids , menstruation , ovarian cysts , systemic lupus erythematosus , liver disease ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Maternal serum AFP (MSAFP) varies by orders of magnitude during the course of a normal pregnancy. MSAFP increases rapidly until about 32 weeks gestation, then decreases gradually. After the pregnancy ends it decreases rapidly, with a half-life of about 5 days. Typically, MSAFP is measured in the beginning of the second trimester (14–16 weeks).
The results of this trial demonstrated a stable disease for 10/18 patients ( 56%) and had no immunogenic response. M5A-DOTA was coupled with 225-Ac , which is an alpa emitter, and an in vivo study was performed where cytokine therapy was combined with a-therapy. [30] The result of the study revealed the benefit of combining these two treamtents.